# Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

> **NCT02008942** · PHASE3 · COMPLETED · sponsor: **PLx Pharma** · enrollment: 57 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** PL2200 Aspirin Capsules
- **DRUG:** Enteric-coated aspirin caplets

## Key facts

- **NCT ID:** NCT02008942
- **Lead sponsor:** PLx Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008942, "Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02008942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*